TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
THRD

Third Harmonic Bio Inc.

Healthcare · Biotechnology

5.40$ +0.0% vs. previous close Closing price · As of: Jul 2, 2026

Ownership

Ownership Structure

Who owns Third Harmonic Bio Inc. (THRD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 34.6% of the shares are freely tradable; institutional investors hold 80.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 80.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 9.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 34.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 5.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 45Mio.

Largest Shareholders

Institutions

Institutions THRD
Name Stake (%) Shares Change (%) Date
Orbimed Advisors, LLC 12.81 5,779,071 +0.0 06/30/2025
BML Capital Management LLC 8.47 3,824,417 +0.0 06/30/2025
Nantahala Capital Management, LLC 6.51 2,938,700 +0.0 06/30/2025
TCG Crossover Management, LLC 4.24 1,915,424 -23.5 06/30/2025
BlackRock Inc 3.83 1,726,614 +16.7 06/30/2025
Vanguard Group Inc 2.88 1,298,089 +11.9 06/30/2025
D. E. Shaw & Co LP 2.77 1,250,680 +118.1 06/30/2025
TANG CAPITAL MANAGEMENT LLC 2.06 929,727 +0.0 06/30/2025
Schonfeld Strategic Advisors LLC 1.71 770,800 +2,460.3 06/30/2025
ADAR1 Capital Management LLC 1.38 622,873 +522.9 06/30/2025

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: July 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?